{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-269398","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.617235+00:00","generated_at":"2026-05-29T09:45:58.742234+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Karyopharm pauses endometrial cancer program update; in talks with FDA about Phase 3 trial","bullets":["Company in discussions with FDA regarding evolving treatment landscape for endometrial cancer and its impact on Phase 3 XPORT-EC-042 trial.","Karyopharm will not discuss endometrial cancer program at Piper Sandler conference on Dec 3, 2024.","Company intends to provide update on endometrial cancer program after FDA discussion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-269398","json":"https://secwatch.observer/filing/0001193125-24-269398.json","markdown":"https://secwatch.observer/filing/0001193125-24-269398.md","text":"https://secwatch.observer/filing/0001193125-24-269398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524269398/0001193125-24-269398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524269398/d916753d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:45:58.742234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}